Skip to main content
. 2017 Oct 24;11:776. doi: 10.3332/ecancer.2017.776

Table 2. Response to pemetrexed between the two cohorts.

Variable Exon 19 (n = 92) Exon 21 (n = 43)
CR (complete response) - -
PR (partial response) 41 18
SD (stable disease) 33 20
PD (Progressive disease) 12 4
Not evaluable 6 9